Eli Lilly and

746.63
14.22 (1.94%)
At close: Apr 14, 2025, 12:33 PM
1.94%
Bid 746
Market Cap 707.8B
Revenue (ttm) 45.04B
Net Income (ttm) 10.59B
EPS (ttm) 11.72
PE Ratio (ttm) 63.71
Forward PE 35.77
Analyst Buy
Ask 747.09
Volume 1,515,936
Avg. Volume (20D) 3,969,300.8
Open 750.45
Previous Close 732.41
Day's Range 734.52 - 755.41
52-Week Range 677.09 - 972.53
Beta 0.50

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...

Sector Healthcare
IPO Date Jun 1, 1972
Employees 47,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Analyst Forecast

According to 24 analyst ratings, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $1008, which is an increase of 35.01% from the latest price.

Stock Forecasts

Next Earnings Release

Eli Lilly and is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 hour ago
Eli Lilly shares are trading higher after Pfizer d... Unlock content with Pro Subscription
3 weeks ago
+0.66%
Eli Lilly shares are trading higher after the company reportedly launched weight loss drug Mounjaro in India at $50 for a 5mg vial.